Laser Transmyocardial Revascularization (TMLR) Combined with Autologous Bone Marrow Cells (ABMC) for Diffuse Coronary Disease (DCD). Results In 19 Cases

• Published in: Blood 2010-11, Vol.116 (21), p.1181-1181
• Main Authors: Alegre, Adrian, Aguado, Beatriz, Alfonso, M. Perez, Muñoz, C., de Landázuri, M. Ortiz, Sanchez, F. Madrid, Cámara, C., García-Fernández, N., Bascones, L., Martinez, S., García-León, N., Roig, M., Duarte, J., Reyes, G.
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V116.21.1181.1181

Abstract 1181 Stem cells (SC) show a potential of cellular therapy in diffuse coronary disease with controverted results. We present here an analysis of a group of patients treated with TMLR plus ABMC. (Caiber Program Advanced Therapy Proyect FIS 2009). 19 patients with DCD were included. Age 66 (range: 52–78). ABMC were obtained by aspiration and processed using HARVEST-TM system -TALEX (Harvest Technologies Inc. GMBH, Munich) to obtain 20 ml. Surgery consisted of anterior thoracotomy incision at the fourth and fifth intercostal space. Between 15–30 transmyocardial channels were realized with TLMR PHOENIX-TM (Cardiogenesis, Irvine, CA, USA) and CrystalFlex 1 mm optical fibre. 0.5–2 cc of MO were administered in each channel. Total number CMN were determined by automatic cell counter and flow cytometry and were typified specific cell populations such as CD34+ and CD133+. The duration of stem cell collection was less than 30 minutes. All the procedure was performed on surgery in 1 step. Any complications were observed with this technique. Correlation between the cellular count and demographic data was not observed. After a follow up of 22 months (5-36) only one patient has died (20m) of DCD. Initial clinical results are satisfactory with a significant reduction in the functional grade of angina. Our data show that TMLR plus ABMC is a safe method with clinical efficacy in patients with DCD that are not candidate to other therapy options. The described method offers efficiency and simplicity to obtain cells. More cases and follow-up are required, as well as later functional evaluations. TABLE 1MEDIAN CMN (×106/ml)MEDIAN CD34+ (×106/ml)MEDIAN CD133+ (×106/ml)Cell therapy product (ABMC)93.6 (43.7–156.8)0.8 (0.1–1.4)0.36 (0.001–0.7) PATIENTSTherapyPost-TreatmentpFunctional angina3.2 ± 0.51.2 ± 0.5